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The homozygous deletion of the phenylalanine at position
508 (DPhe508) in the first nucleotide-binding domain
(NBD1) of the cystic fibrosis transmembrane conductance
regulator (CFTR) is the most common CF-causing
genetic defect. It has been proposed that the propensity of
NBD1 to aggregate may lead to a lower display of the
CFTR chloride channel to the cell membrane and to the
disease, thus opening an avenue for the pharmacological
development of CFTR folding correctors. Here, we show
that a human monoclonal antibody fragment specific to
the folded conformation of NBD1 inhibits the aggregation
of NBD1 in vitro. However, in contrast to the previously
published observations, we proved experimentally that
NBD1 of wild-type and DPhe508 version of CFTR display
comparable propensities to aggregate in vitro and that the
corresponding full-length CFTR protein reaches the cell
membrane with comparable efficiency in mammalian cell
expression systems. On the basis of our results, the
‘folding defect’ hypothesis seems unlikely to represent the
causal mechanism for the pathogenesis of CF. A solid
understanding of how the DPhe508 deletion leads to the
disease represents an absolute requirement for the devel-
opment of effective drugs against CF.
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Introduction
Certain mutations in the cystic fibrosis transmembrane con-
ductance regulator (CFTR), an integral membrane protein,
can cause CF, the most common hereditary monogenic
disease which affects the entire body, leading to progressive
disability and early death (Kerem et al., 1997). CF com-
monly manifests with pancreatic insufficiency, elevated
sweat chloride concentration and male infertility. The most
striking CF phenotype is seen in airways where chronic pul-
monary infections arise from bacterial pathogens. The homo-
zygous deletion of the phenylalanine at position 508
(DPhe508) in the first nucleotide binding domain (NBD1) of
CFTR is the most common CF-causing mutant, accounting
for 70% of the CF patients worldwide, yet its frequency
varies between ethnic groups, e.g. 82% of CF patients have
homozygous DPhe508 in Denmark versus 32% in Turkey
(Ratjen and Doring, 2003).
The monogenic nature of the genetic defects in CF makes
this disease an attractive candidate for somatic gene therapy,
but limited extent and duration of the corrections as well as
concerns about the safety of currently available delivery
systems have prevented gene therapy from being curative
(Ziady and Davis, 2006). Transgene expression should be
conserved over the lifetime of the patient. Repeated adminis-
trations of both viral and non-viral vectors are hampered by
host immunity and low transfection efficiency. Moreover,
access of vectors to target cells from the airways is hindered
by the thick mucus layer of CF lung. These serious chal-
lenges for the gene therapy of CF have stimulated the search
for pharmacological agents, an activity which requires a
solid understanding of the molecular mechanism by which
the DPhe508 deletion causes the disease.
Some 20 years after the identification of CFTR mutations
as the cause of CF, two alternative theories have been pro-
posed as mechanisms of pathogenesis: the ‘folding hypoth-
esis’ (according to which CFTR mutations would lead to
reduced protein display on the cell membrane) and the
‘abnormal gating hypothesis’ (according to which mutations
lead to abnormal channel function).
The DPhe508 deletion has been postulated to give rise to a
temperature-sensitive folding defect of the CFTR channel,
evidenced by failure of the full-length protein to mature
(Denning et al., 1992) and by retention in the endoplasmic
reticulum and subsequent degradation (Kopito, 1999). The
observation that the folding defect of CFTRDPhe508 could
be corrected by growing cells at lower temperature (Denning
et al., 1992) suggests that molecules capable of stabilizing
the folded conformation of CFTR may facilitate the develop-
ment of drugs which act by increasing folding yields (‘cor-
rectors’) and/or by increasing the specific ion channel
activity (‘potentiators’).
The temperature-dependent folding defect postulated by
Denning et al. (1992) on the basis of studies of CFTR
glycosylation in stably transfected 3T3 fibroblasts is not in
complete agreement with experimental evidence of protein
expression in vivo. First, a careful immunohistochemical
analysis of CFTR expression in normal tissues and in CF
samples revealed similar levels of protein expression in lung
and intestine. However, different levels of CFTR expression
were observed in the luminal surface of reabsorptive ducts of
sweat glands (Kalin et al., 1999). Second, transient transfec-
tions of insect cells with CFTR and CFTRDPhe508 revealed
comparable glycosylation patterns and similar expression
levels at 278C. The proteins, when purified and reconstituted
in vitro, demonstrated comparable activities (Li et al., 1993).
Moreover, a study performed on immortalized epithelial cells
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obtained from healthy donors and CF patients revealed a
comparable expression pattern both in terms of protein
amount, glycosylation and membrane distribution (Sarkadi
et al., 1992).
The folding defect hypothesis is supported by the
observation that the DPhe508 form of recombinantly
expressed NBD1 exhibited a temperature-sensitive tendency
to aggregate in in vitro refolding experiments, which was
more severe compared with the wild-type (wt) protein.
Folding yields were measured by diluting a concentrated
solution of denatured recombinant NBD1 into a suitable
refolding buffer, followed by overnight incubation, centri-
fugation to remove precipitated protein and fluorescence-
based detection of the fraction of soluble NBD1 (Qu and
Thomas, 1996; Thibodeau et al., 2005). However, the method
did not feature a direct detection of the amount of pre-
cipitated protein: a decrease in fluorescence signal could in
principle result both from protein precipitation and from
the hypofluorescence associated with the denatured form of
the protein. The DPhe508 form of the recombinant NBD1,
containing residues 404–589, was reported to display a
slightly reduced folding yield compared with the wt counter-
part, both at 2 and 18 mM concentration (Qu and
Thomas, 1996). In contrast, the longer version (residues
389–655) of the NBD1 was reported to exhibit a dramatic
difference in folding efficiency, with the wt protein being
completely folded and soluble at 108C, whereas the
DPhe508 form exhibited only 50% folding yield at the same
temperature (Thibodeau et al., 2005). According to these
experiments, the different in vitro refolding behavior of
the two versions of the NBD1 proteins would recapitulate
the folding defects observed in cellular systems for the
full-length CFTR proteins (Denning et al., 1992) and could
represent the basis for the high-throughput screening of
folding correctors.
The ‘abnormal gating hypothesis’ mainly relies on exper-
imental data in cell lines (Hwang et al., 1997) and in
Xenopus oocytes (Treharne et al., 2007), indicating that the
DPhe508 deletion in CFTR leads to impaired halide transport
in model cellular systems. CFTR is a major epithelial ion
channel in the apical membrane of the highly active salt
absorptive duct of the human sweat gland (Reddy and
Quinton, 2006), and patients with CF typically have
increased salt concentrations in sweat.
In this article, we report that in our hands the previously
published differences in in vitro folding yields of wt and
DPhe508 NBD1 proteins could not be reproduced. In a
variety of experimental conditions and using the previously
described recombinant versions of the NBD1 (residues
404–589 and 389–655), we observed a comparable tem-
perature and time-dependent profile of protein precipita-
tion for both wt and DPhe508 forms. Additionally, both
transient and stable transfection experiments performed
with vectors encoding the full-length wt and DPhe508
forms of CFTR led to comparable levels of channel display
on the surface of CHO cells, LM fibroblasts and SP2/0
cells, as revealed by fluorescence-activated cell sorting
(FACS) analysis. Interestingly, the folding defects of both wt
and DPhe508 forms of NBD1 could be corrected in the pre-
sence of a monoclonal antibody fragment specific to the
native form of the protein. These results indicate that folding
correction may be achieved with molecular agents which
stabilize the folded conformation of NBD1, but at the same
time underline the need for a critical re-evaluation of the
claimed contribution of folding defects to the pathogenesis
of CF.
Materials and methods
Protein cloning, expression and purification
Unless stated otherwise, chemicals were purchased from
Fluka.
The gene coding for the fragment 404–589 of CFTRwt
was PCR amplified from a human cDNA library (Human
MTC Panel I, Clontech) with primers Gly-404 (50-ATAGG
ACATATGGGATTTGGGGAATTATTTGAGAAAGC-30)
and Ser-589 (50-ATAGGACTCGAGTTAGCTTTCAAATAT
TTCTTTTTCTGTTAAAAC-30) and cloned in pET28 vector
(Novagen) using the restriction sites NdeI and XhoI.
The gene coding for the fragment 389–655 of CFTRwt
was PCR amplified from a human cDNA library (Human
MTC Panel I, Clontech) with primers Thr-389 (50-GGG
AATTCCATATGACTACAGAAGTAGTGATGGAGAAT-
G-30) and Ala-655 (50-CCGCTCGAGTTATGCACTAAATT
GGTCGAAAGAATC-30) and cloned in pET28 vector using
the restriction sites NdeI and XhoI. The genes coding for the
fragment 404–589 of CFTRwt and 389–655 of CFTRwt
were PCR mutated in order to delete the phenylalanine
residue at position 508: the deletion was introduced with
primers 508bw (50-GGTGTTTCCTATGATGAATATAGATA
C-30) and 508mut (50-TCTATATTCATCATAGGAAA
CACCGATGATATTTTCTTTAATGGTGCCAG-30) and
cloned in pET28 vector using the restriction sites NdeI and
XhoI. BL21 (DE3) Escherichia coli (Invitrogen) was trans-
formed with pET28–NBD1(404–589)wt, pET28–NBD1
(404–589)DPhe508, pET28–NBD1(389–655)wt or pET28–
NBD1(389–655)DPhe508. The corresponding proteins,
which contain an initial GSSHHHHHHSSGLVPRGSHM
sequence followed by amino acids 404–589 (GFGELFEKA
KQNNNNRKTSNGDDSLFFSNFSLLGTPVLKDINFKIER-
GQLLAVAGSTGAGKTSLLMMIMGELEPSEGKIKHSGRI-
SFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEE
DISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDAD
LYLLDSPFGYLDVLTEKEIFES) or by amino acids 389–
655 (TTEVVMENVTAFWEEGFGELFEKAKQNNN NRKT
SNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGST-
GAGKTSLLMMIMGELEPSEGKIKHSGRISFCSQFSWIMP
GTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNI-
VLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGY-
LDVLTEKEIFESCVCKLMANKTRILVTSKMEHLKKAD-
KILILNEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQF-
SA), were expressed as described below.
After transformation of BL21 (DE3) cells, colonies har-
boring NBD1 constructs were inoculated in 100 ml 2  YT
medium (Q-BIOgene) containing 30 mg/ml kanamycin
(Applichem) and 1% (w/v) glucose (Sigma-Aldrich) and
grown overnight at 308C in a rotary shaker at 200 rpm. A
volume of 5 ml from the overnight pre-culture was then
inoculated into 1000 ml 2  YT medium containing 30
mg/ml kanamycin and 0.1% (w/v) glucose and grown at
378C in a rotary shaker at 200 rpm until the absorbance at
600 nm reached a value between 0.4 and 0.6. Protein
expression was induced by the addition of 1 mM IPTG
V.Lovato et al.
608
(Applichem). After 4 h at 378C in a rotary shaker (200 rpm),
the bacterial cells were harvested by centrifugation and resus-
pended in 6 ml buffer W1 (20 mM Tris, 500 mM NaCl, 6 M
Guanidine hydrochloride, 5 mM Imidazole, pH 7.9). After
cell lysis by sonication (Vibracell CV33, SONICS), the
lysate was centrifuged for 20 min at 47 800 g. The cleared
lysate was mixed with 4 ml of Ni2þ-NTA slurry (Qiagen) to
capture the 6  His tagged proteins and the mixture was
incubated at 48C for 1 h while shaking on a rotary shaker.
The resin was washed first with 20 ml buffer W1, then with
buffer W2 (20 mM Tris, 500 mM NaCl, 6 M Guanidine
hydrochloride, 20 mM Imidazole, pH 7.9) until the absor-
bance at 280 nm of the eluate was lower than 0.1. The
protein was eluted by the addition of 12 ml buffer E (20 mM
Tris, 500 mM NaCl, 6 M Guanidine hydrochloride, 400 mM
Imidazole, pH 7.9). After elution, the protein was dialyzed
overnight at 48C against buffer D (20 mM Tris, 6 M
Guanidine hydrochloide, 1 mM DTT, pH 8.0). The protein
stock was concentrated by centrifugation with Vivaspin tubes
(10 000 MWCO PES, Vivascience) and stored at 2208C.
SDS–PAGE (Invitrogen) analysis was performed on samples
after overnight ethanol precipitation, to avoid the presence of
Guanidine hydrochloride.
The correctness of the cloning was confirmed by sequen-
cing using an ABI PRISM 3130 Genetic Analyzer (Applied
Biosystem). Furthermore, the proteins were characterized by
analyzing their tryptic digests by MALDI-TOF/TOF mass
spectrometry. Both proteins were digested overnight with
trypsin (Promega). Resulting peptides were measured on a
4700 Proteomic Analyzer (Applied Biosystems) and the
spectra were analyzed using the GPS Explorer and the Data
Explorer software (Applied Biosystems).
Refolding experiments
Aliquots of purified NBD1wt or NBD1DPhe508 stocks were
diluted 30-fold with buffer B (100 mM Tris, 400 mM
L-arginine, 2 mM EDTA, 1 mM DTT, pH 8.0) to a final
protein concentration of 1–20 mM. The refolding step was
performed at 48C using tips, tubes and solutions previously
equilibrated at 48C in order to avoid any unwanted protein
precipitation. Samples were incubated at different tempera-
tures, from 48C to 378C, and for different time gaps. After
incubation, samples were centrifuged for 10 min at 15 700 g
and 48C, to remove insoluble misfolded protein.
Temperature dependence of NBD1 folding:
tryptophan fluorescence
In order to study the temperature dependence of folding,
NBD1(389–655)wt and NBD1(389–655)DPhe508 were
refolded, incubated overnight and centrifuged as described
above. After centrifugation, tryptophan fluorescence emission
spectra of supernatants were collected. Samples were ana-
lyzed with the spectrofluorometer LS50b (Perkin Elmer),
using 282 nm excitation light and monitoring emission
between 300 and 400 nm. The peak value of protein refolded
and incubated at 48C was considered as corresponding to
100% of soluble protein.
Temperature dependence of NBD1 folding: SDS–PAGE
In order to study the temperature dependence of folding,
NBD1wt and NBD1DPhe508 were refolded, incubated and
centrifuged as described above. After centrifugation, pellets
and supernatants were separated, pellets were dissolved and
supernatants were diluted to the same final volume by adding
H2O and gel loading buffer (0.2 M Tris, 30% glycerol,
230 mM Sodium dodecyl sulfate, 1 mM Bromophenol Blue).
Ten microliters of pellet and supernatant samples were ana-
lyzed by SDS–PAGE (10% Bis–Tris Gel, Invitrogen).
Antibody selection
Human monoclonal antibodies specific to NBD1DPhe508
were isolated by biopanning from the ETH2-Gold antibody
phage display library, previously described by our group
(Viti et al., 2000; Silacci et al., 2005). Biopanning exper-
iments were performed on immunotubes coated with recom-
binant NBD1DPhe508 following standard procedures (Viti
et al., 2000), confirming antigen binding both by ELISA on
microtiter plates and by antigen immobilization on a Biacore
CM-5 biosensor chip (Biacore). The isolated clones were
sequenced using an ABI PRISM 3130 Genetic Analyzer
(Applied Biosystem). One of the NBD1-binding scFv frag-
ments (‘C2’) was tested for its folding stabilizing effect.
Temperature-dependent folding experiments were performed
as described above, adding equimolar amounts of scFv C2 to
the folding buffer just before addition of NBD1. Samples
were incubated at different temperatures for increasing time
intervals and prepared for SDS–PAGE analysis as described
above.
FACS analysis of transfected mammalian cells
CHO-S cells (GIBCO, Invitrogen) were transfected (Gene
Pulser, Bio-Rad) with pcDNA3.1 vector containing the
coding sequence for either CFTRwt or CFTRDPhe508
(vectors kindly provided by Prof. Galietta). After electropora-
tion, cells were grown at 378C for 72 h in CD CHO medium
(GIBCO, Invitrogen) including HT Supplement (GIBCO,
Invitrogen).
LM fibroblasts (ATCC, CCL-1.2) were transfected with
pcDNA3.1 vector containing the coding sequence for either
CFTRwt or CFTRDPhe508, with the transfection reagent
Lipofectamine 2000 (Invitrogen). After transfection, cells
were grown at 378C for 48 h in DMEM medium (GIBCO,
Invitrogen) including fetal bovine serum (FCS, GIBCO,
Invitrogen) and antibiotic–antimycotic (GIBCO, Invitrogen).
SP2/0 cells (ATCC, CRL-1581) were transfected
(Nucleofector, Amaxa) with pcDNA3.1 vector containing the
coding sequence for either CFTRwt or CFTRDPhe508. After
transfection, cells were grown at 378C for 48 h in CD
Hybridoma medium (GIBCO, Invitrogen) including
L-Glutamine (GIBCO, Invitrogen) and antibiotic–antimyco-
tic (GIBCO, Invitrogen).
Cells were harvested and diluted in PBS containing 1%
FCS (FPBS) to a 5  106 cell/ml concentration: 200 ml of
this cell solution were used for each single staining. Cells
were spun at 292 g for 5 min, the supernatant was discarded
and 100 ml of a 2 ml/ml solution of the primary antibody
(mouse monoclonal [CF3] to CFTR, Ab2784, Abcam) was
added to the cells. Cells were incubated for 20 min at 48C.
After incubation, cells were spun at 292 g for 5 min, the
supernatant was discarded and 100 ml of a 50 ml/ml solution
of the secondary antibody (R-Phycoerithrin-Conjugated Rat
Anti-Mouse IgM Monoclonal Antibody, BD Pharmingen)
was added to the cells. Cells were incubated for 20 min at
48C in the dark. After incubation, cells were spun at 292 g
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for 5 min, the supernatant was discarded and cells were
washed by adding 200 ml of FPBS. Cells were immediately
spun at 292 g for 5 min, the supernatant was discarded and
cells were finally resuspended in 100 ml of FPBS. Cell
samples were stored at 48C in the dark before analysis with a
BD FACSCanto Flow Cytometer (BD Biosciences).
Results
In vitro refolding experiments with recombinant NBD1wt
and NBD1DPhe508 proteins
We cloned and expressed in E.coli the wt and DPhe508 form
of the NBD1 domain containing residues 404–589 and 389–
655, carrying a 6  His-tag at the N-terminus of the protein.
The putative amino acid sequence for all four proteins var-
iants was identical to the one described in previous publi-
cations (Qu and Thomas, 1996; Thibodeau et al., 2005).
Figure 1 shows a portion of the mass-spectrometric charac-
terization performed on the recombinant 389–655 versions
of the NBD1 domain. A protein coverage of 78.7% for both
proteins could be confirmed with tryptic peptides, including
an unambiguous detection of N- and C-terminal peptides and
a detected mass difference of 147.07 Da for the tryptic pep-
tides corresponding to residues 136–148 of NBD1wt and to
residues 136–147 of NBD1DPhe508.
In order to shed light on the mechanism of incomplete
folding yields (i.e. low fluorescence values could be due to
either protein precipitation during the overnight incubation
and/or lower fluorescence intensities for soluble protein in
the unfolded conformation), we performed an SDS–PAGE
analysis of protein refolding, separating soluble and insoluble
protein by centrifugation. The short version of recombinant
NBD1, containing residues 404–589, displayed to be soluble
when incubated at 48C (Fig. 2). Incubating the NBD1(404–
589) protein samples at 228C resulted in growing amounts of
insoluble protein at increasing incubation time (Fig. 2).
These data demonstrate how increasing incubation time and
temperature will result in increment of insoluble protein.
However, the wt and mutant versions of the NBD1(404–
589) failed to display any differences in aggregation rate.
Using the same experimental procedure, we then analyzed
the folding behavior of the 389–655 versions of the NBD1
domain. Figure 3 shows a representative analysis of several
refolding experiments performed at different times and temp-
eratures. As for the shorter version of the protein, we could
confirm that at increasing temperatures and incubation times,
NBD1(389–655) would yield increasing amounts of insolu-
ble protein, as previously described in other works (Qu and
Thomas, 1996; Thibodeau et al., 2005). However, in our
hands, no significant difference could be detected between
the NBD1(389–655)wt and the corresponding NBD1(389–
655)DPhe508 mutant, in clear contrast with the data reported
by Thibodeau and coworkers. Similarly, we did not observe
differences in folding yield between the two forms of the
NBD1(389–655) using fluorescence detection methodologies
(Fig. 4).
Fig. 1. Mass spectra of tryptic peptides of wt and DPhe508 NDB1(389–
655). The two spectra show comparable peak profiles. Only two peaks are
different, with a mass difference corresponding to the monoisotopic mass of
phenylalanine. MALDI-TOF/TOF analyses of these two peaks led to
identification of the peptide ENIIFGVSYDEYR in the wt spectrum and the
peptide ENIIGVSYDEYR in the DPhe508 spectrum. The sequences of the
main peptide peaks are indicated.
Fig. 2. SDS–PAGE analysis of NBD1 folding efficiency. NBD1(404–589)wt and NBD1(404–589)DPhe508 proteins were refolded by dilution to roughly
20 mM final concentration as described in the text (see ‘Materials and methods’). Samples were incubated for increasing times at the indicated temperatures
and, after centrifugation, pellets (P) and supernatants (S) were separated and analyzed. Input (I) corresponds to not centrifuged samples. Each time point
includes 10 min centrifugation (i.e. 30 min stands for 20 min of incubation plus 10 min of centrifugation). The overnight (ON) incubation corresponds to 16 h.
NBD1(404–589)wt and NBD1(404–589)DPhe508 proteins were soluble after overnight incubation at 48C. Both proteins showed comparable amounts of pellet
after the same incubation time at 228C.
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Refolding of NBD1 in presence of a human monoclonal
antibody specific to NBD1
Attempts to increase the recovery of soluble folded NBD1
proteins at higher temperatures failed (data not shown) in the
presence of 1 mM ATP, 1 mM TNP–ATP (an
ATP-analogue) and 1 mM concentrations of drugs such as
BayK-8644, Curcumin and Genistein, which are under con-
sideration for CF therapy (Weinreich et al., 1997; Davis and
Drumm, 2004; Pedemonte et al., 2005).
In order to determine whether a binder, endowed with suf-
ficient affinity and specificity for the NBD1 domain, could
stabilize the folded conformation of this protein and reduce
precipitation, we generated human monoclonal antibody frag-
ments in scFv format from a large synthetic phage display
library recently cloned in our group (Silacci et al., 2005).
One of the resulting monoclonal antibodies (clone C2;
Table I) exhibited a comparable binding affinity to both
NBD1wt and NBD1DPhe508 and was thus used as additive
in refolding experiments. The scFv(C2) exhibited a substan-
tial improvement in the recovery of soluble NBD1(389–655)
domain, when analyzing the NBD1 refolding experiment by
SDS–PAGE (Fig. 5), indicating that NBD1-binding mol-
ecules may indeed help stabilize the soluble, folded confor-
mation of this protein.
Fig. 3. SDS–PAGE analysis of NBD1 folding efficiency. NBD1(389–655)wt and NBD1(389–655)DPhe508 proteins were refolded by dilution to 8 mM final
concentration as described in the text (see ‘Materials and methods’). Samples were incubated for increasing times at the indicated temperatures and, after
centrifugation, pellets (P) and supernatants (S) were separated and analyzed. Input (I) corresponds to not centrifuged samples. Each time point includes 10 min
centrifugation (i.e. 30 min stands for 20 min of incubation plus 10 min of centrifugation). The overnight (ON) incubation corresponds to 16 h. NBD1(389–
655)wt and NBD1(389–655)DPhe508 proteins were soluble after overnight incubation at 48C. Both proteins showed comparable amounts of pellet after the
same incubation time at 168C and 378C.
Fig. 4. NBD1 folding efficiency as a function of folding temperature.
NBD1(389–655)wt and NBD1(389–655)DPhe508 proteins were refolded by
dilution to 1 mM final concentration as described in the text (see ‘Materials
and methods’). Samples were incubated overnight at the indicated
temperatures, and after centrifugation, fluorescence emission spectra of the
supernatants were collected. The relative folding yield was determined as the
fraction of tryptophan fluorescence emission intensity. Samples were excited
at 282 nm and emission spectra were collected from 300 to 400 nm. The
peak value detected on samples incubated at 48C was considered as
corresponding to 100% of soluble protein.
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Cell transfection with vectors coding for CFTRwt
and CFTRDPhe508
Puzzled by the discrepancy between the results of our
in vitro refolding experiments with the NBD1 domain and
the previously published data, we decided to critically evalu-
ate the levels of membrane expression of CFTR for the wt
and DPhe508 version of the protein in a model cellular
system. To this aim, we transfected CHO cells, LM fibro-
blasts and SP2/0 cells with vectors coding either for the wt
or for the DPhe508 version of CFTR. The transfections of
the different cell lines were performed in parallel, using iden-
tical amounts of plasmids and number of cells. After trans-
fection, cells were cultured at 378C. The amount of CFTR
protein displayed at the plasma membrane of both transiently
and stably transfected cells was detected by FACS using the
monoclonal antibody Ab2784 (Abcam), which recognizes an
extracellular portion of the CFTR protein (Walker et al.,
1995). The analysis of transiently transfected CHO-S cells
shows a similar increase of FACS signal for both the wt and
the DPhe508 version of the protein, compared with the
untransfected controls (Fig. 6a). Similar results were
obtained when analyzing transiently transfected LM fibro-
blasts (Fig. 6b) and SP2/0 cells (Fig. 6c), which also revealed
comparable levels of wt and DPhe508 protein display on the
cell membrane.
Discussion
Almost 20 years after the discovery that the DPhe508 del-
etion in CFTR is the most frequent cause of CF (Riordan
et al., 1989; Rommens et al., 1989), the mechanisms for the
pathogenesis of the disease are still poorly understood. The
results of this article on one hand show for the first time that
molecular correctors can be identified which rescue folding
defects of NBD1 in vitro, but at the same time cast doubts
about the validity of the ‘folding defect’ hypothesis for the
pathogenesis of CF. Some of the previously published
Table I. Aminoacid sequence of scFv (C2)
Heavy chain EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSV
KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMRLGLFDYWGQGTLVTVSS
Linker GGGGSGGGGSGGGG
Light chain EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGS
GSGTDFTLTISRLEPEDFAVYYCQQRGDVPPTFGQGTKVEIKAAAEQKLISEEDLNGAA-
The amino acid sequence of the human monoclonal antibody C2 selected against NBD1 is represented in the table. The scFv is composed of a heavy chain, a
linker (indicated in italic) and a light chain; the light chain includes a myc tag that is underlined in the table. The randomized CDR3 regions in the synthetic
antibody library used for antibody selection (Silacci et al., 2005) are displayed in bold.
Fig. 5. SDS–PAGE analysis of NBD1 folding efficiency in the presence of scFv C2. NBD1(389–655)wt and NBD1(389–655)DPhe508 proteins were
refolded by dilution in folding buffer, with or without equimolar amounts of scFv C2, to 8 mM final concentration as described in the text (see ‘Materials and
methods’). The NBD1-binding scFv C2 antibody fragment runs at 27 kDa. Samples were incubated for increasing times at 258C and, after centrifugation,
pellets (P) and supernatants (S) were separated and analyzed. After 1 and 3 h of incubation at 258C, NBD1(389–655)wt and NBD1(389–655)DPhe508
proteins refolded in the presence of scFv C2 and remained soluble, whereas the corresponding samples incubated in folding buffer without scFv C2 were found
in the pellet.
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reports on differential CFTR expression relied on expression
studies with monoclonal cell lines (Egan et al., 2004). It is
well established that cells stably transfected with a given
vector typically yield monoclonal cell lines which may differ
in protein expression by several orders of magnitude
(Newman and Mann, 2007).
It has been proposed that the DPhe508 deletion in CFTR
leads to impaired halide transport in model cellular systems
both using stable transfections for CFTR expression (Hwang
et al., 1997) and, importantly, cRNA injection in Xenopus
oocytes (Treharne et al., 2007). However, we strongly feel
that differences in ion transport efficiency should be assessed
in the context of the patterns of CFTR expression in different
tissues and their pathophysiological implications (Kalin
et al., 1999).
One of the most attractive areas of modern CF research
focuses on the characterization of the CF ‘interactome’ (i.e.
the set of proteins which may interact directly or indirectly
with CFTR) (Ollero et al., 2006; Wang et al., 2006; Treharne
et al., 2007). It has recently been suggested that the DPhe508
deletion impairs CK2-mediated binding to NBD1 and the
phosphorylation of Ser511 within the domain (Treharne
et al., 2007), with profound consequences on CFTR channel
gating. Mutation of Ser511 within CFTR phenocopies the
effect of the DPhe508 deletion. If these results are confirmed,
it appears that pharmacological research activities should
ideally be focused on the identification of selective channel
potentiators. In turn, these activities will most likely rely on
the identification of specific CFTR-binding molecules.
The finding that the folding defects of both wt and
DPhe508 forms of NBD1 could be corrected in the presence
of a monoclonal antibody fragment specific to the native
form of the protein gives hope that NBD1-binding molecules
may help stabilize the soluble, folded conformation of this
protein. Such a concept has previously been demonstrated for
antibody and peptides molecules recognizing mutant, desta-
bilized p53 transcription factor in the field of cancer research
(Issaeva et al., 2003; Weisbart et al., 2004). From a chemical
point of view, the ‘minimization’ of protein-based binders
(Braisted and Wells, 1996) or the functional antibody repla-
cement with small organic molecules (Melkko et al., 2007)
both represent formidable challenges.
Moreover, the strategy of using small molecules that
stabilize a mutant protein and consequently restore trafficking
and activity, an approach called molecular chaperoning, has
been successfully applied to the lysosomal enzyme acid
b-glucosidase (GCase, Lieberman et al., 2007). Mutations in
the GCase protein destabilize the native conformation of the
enzyme leading to the Gaucher disease. The ability to stabil-
ize the right protein conformation may be the hallmark of a
molecule with therapeutic effect.
In summary, we have generated a monoclonal antibody
fragment which prevents the aggregation of the NBD1
domain of both wt and DPhe508 versions of CFTR. At the
same time, we have provided evidence for comparable levels
of expression of the full-length CFTR protein in mammalian
cells. This observation weakens the ‘folding defect’ hypoth-
esis, which is still frequently invoked as the causal mechan-
ism of CF (Wang et al., 2006). However, CFTR mutations
do lead to abnormal protein expression only in certain
tissues, most notably the sweat gland ducts. The reasons for
these tissue-specific defects of protein production are not
known at present. A better understanding of the molecular
mechanisms for the pathogenesis of CF is urgently needed,
in order to provide a rational basis for the development of
effective drugs for the pharmacological treatment of this
disease.
Fig. 6. FACS analysis of CHO-S cells (a), LM fibroblasts (b) and SP2/0 cells (c). The negative controls are shown on the left panels, the cells transfected
with pcDNA3.1–CFTRwt vector in the central panels and with pcDNA3.1–CFTRDPhe508 vector in the right panels. Each sample was incubated both with
primary and secondary antibodies (see ‘Materials and methods’). The percentage of cell population giving a fluorescence signal corresponding to detection of
CFTR is indicated in each panel.
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